by David Wallace Patients are Asking – Episode 2 of 3 In this interview with MPN expert, Dr. Angela Fleischman, we discuss the latest treatments for myelofibrosis (MF) and when a clinical trial should be considered. Research has linked MPNs to a pre-disposition to autoimmune disorders such as Lupus, Crohn’s disease and Psoriasis just to […]
Access to comprehensive support is a “must have” in managing PV
Sponsored Post An interview with Christina Liston, Director of Patient Access at PharmaEssentia It’s no secret in the polycythemia vera (PV) community that the patient journey comes with many challenges, sometimes feeling like a roller coaster ride. It impacts us at a physical, mental, and spiritual level. For many people, the disease comes with a […]
MPN Patient Advocacy Works!
by David Wallace I got my first shot of Pegasys 3 days ago, along with my local doctor’s agreement to monitor my counts. It was not without a HARD push on my part, as Doc was still pushing the benefits of HU (hydroxyurea), while reinforcing the numerous risks with Peg. For once, I was glad […]
Pregnancy and Childbirth Outcomes in Women with MPNs
A Nationwide population-based study of 342 pregnancies in Sweden Abstract Pregnancy and childbirth in women with myeloproliferative neoplasms (MPN) are reported to be associated with maternal thrombosis, hemorrhage, and placental dysfunction. To assess the risks of adverse events in pregnancy in women with MPN, we performed a large population-based study using Swedish health care registers, […]
MPN Awareness Day!
by David Wallace Today we celebrate MPN Awareness Day with our community! We are focused 24/7 on providing valuable resources to patients, caregivers and healthcare providers via our websites PV Reporter and MPN Cancer Connection. MPN Awareness and education is a daily practice rather than a special event. —> For myself personally, I take great […]
Paving the way to improve therapy for MPNs
Megan Bywater & Steven W. Lane, Nature Communications volume 13, Article number: 5025, Published: August 26, 2022 Long-acting IFNα induces durable molecular responses in myeloproliferative neoplasms. Emerging studies, including Saleiro et al. recently published in Nature Communications, have identified promising candidates that may synergize with IFNα by targeting stem cell function or feedback loops that mediate […]
Treatments for ET and PV Moving Towards Disease Modification
by Christina T. Loguidice, OncLive Prevention and mitigation of cardiovascular events, such as thrombohemorrhagic complications, have been the main goal of treatment development for patients with essential thrombocythemia and polycythemia vera. Prevention and mitigation of cardiovascular events, such as thrombohemorrhagic complications, have been the main goal of treatment development for patients with essential thrombocythemia (ET) […]
Can Polycythemia Vera Patients Live a Normal Lifespan?
by David Wallace Transcript | Can Polycythemia Vera (PV) Patients Live a Normal Lifespan? David Wallace: So you had several important abstracts and one that our listeners with PV will be excited about. So tell us about the potential for normal life expectancy in PV. Dr. Abu-Zeinah: So this a project was inspired by our […]
What is Blood Cancer?
Someone around the world is diagnosed with blood cancer every 35 seconds (every 3 minutes in the U.S.)… but what does this mean? With over 137 different types of blood cancer and blood disorders, it can be difficult to understand what exactly is meant by the term ‘blood cancer.’ This video uses a medical approach […]
Impact of Anti-Endothelial Cell Antibodies in Patients with Polycythemia Vera and Thrombosis
Physicians should consider measuring anti-endothelial cell antibodies in patients with polycythemia vera, the investigators suggested. A new analysis of anti-endothelial cell antibodies (AECAs) in patients with polycythemia vera (PV) suggests that autoimmunity may be one mechanism by which thrombosis develops. Abstract Polycythemia vera (PV) causes thrombosis. Erythrocytosis and cell adhesiveness are responsible for thrombosis. JAK2V617F causes inflammation […]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 21
- Next Page »
